Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 4/20 | 0.63 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.63 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.55 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.55 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.54 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22432716 | 0.92 | HRH3 (0.60) | ADRB3ADRB2ADRB1ACHEPDK1 | |
| SCHEMBL9194405 | 0.85 | HRH3 (0.53) | ADRB3ADRB2ADRB1ACHEPDK1 | |
| SCHEMBL3530973 | 0.84 | ADRB3 (0.48) | ADRB3ADRB2ADRB1ACHEPDK1 | |
| SCHEMBL8196267 | 0.83 | TAAR1 (0.64) | ADRB3ADRB2ADRB1ACHEPDK1 | |
| SCHEMBL3189233 | 0.81 | ACHE (0.56) | ADRB3ADRB2ADRB1ACHEPDK1 | |
| SCHEMBL8141384 | 0.80 | HRH3 (0.59) | PDK1PDK2PDK3PDK4HRH3 | |
| SCHEMBL28757282 | 0.80 | HRH3 (0.63) | PDK1PDK2PDK3PDK4HRH3 | |
| SCHEMBL13279482 | 0.78 | HRH3 (0.49) | ADRB3ADRB2ADRB1PDK1PDK2 | |
| SCHEMBL29880799 | 0.78 | ADRB3 (0.50) | ADRB3ADRB2ADRB1ACHE | |
| SCHEMBL8118083 | 0.78 | ADRB3 (0.50) | ADRB3ADRB2ADRB1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127206-A1 | METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-04-28 | — | — | US | disclosed |
| EP-3939954-A1 | METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2022-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127206-A1 | METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE | MGMT, FANCD2, ADAR | ADRB3 2259/4885ADRB2 1831/4885ADRB1 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.